About laekna inc - LAEKF
Laekna, Inc. engages in the provision of clinical stage research and development of biopharmaceutical products. It primarily focuses on cancer and liver fibrosis. The company was founded by Xiang Yang Lu on July 29, 2016 and is headquartered in Shanghai, China.
LAEKF At a Glance
Laekna, Inc.
Zhangjiang Hi-Tech Park
Shanghai, Shanghai 201203
| Phone | 86-185-1622-6288 | Revenue | 14.85M | |
| Industry | Biotechnology | Net Income | -31,900,905.18 | |
| Sector | Health Technology | Employees | 83 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LAEKF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 45.68 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -13.991 |
| Enterprise Value to Sales | 34.677 |
| Total Debt to Enterprise Value | 0.034 |
LAEKF Efficiency
| Revenue/Employee | 178,866.297 |
| Income Per Employee | -384,348.255 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.089 |
LAEKF Liquidity
| Current Ratio | 5.543 |
| Quick Ratio | N/A |
| Cash Ratio | 5.499 |
LAEKF Profitability
| Gross Margin | 75.871 |
| Operating Margin | -252.963 |
| Pretax Margin | -214.88 |
| Net Margin | -214.88 |
| Return on Assets | -19.103 |
| Return on Equity | -22.855 |
| Return on Total Capital | -17.133 |
| Return on Invested Capital | -22.802 |
LAEKF Capital Structure
| Total Debt to Total Equity | 10.238 |
| Total Debt to Total Capital | 9.287 |
| Total Debt to Total Assets | 8.541 |
| Long-Term Debt to Equity | 0.118 |
| Long-Term Debt to Total Capital | 0.107 |